KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity | Zendy

Laurent Poirel | Zendy; Xavier Vuillemin | Zendy; Mario Juhas | Zendy; Amandine Masseron | Zendy; Ursina Bechtel-Grosch | Zendy; Simon Tiziani | Zendy; Stefano Mancini | Zendy; Patrice Nordmann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity

Author(s) -

Laurent Poirel,

Xavier Vuillemin,

Mario Juhas,

Amandine Masseron,

Ursina Bechtel-Grosch,

Simon Tiziani,

Stefano Mancini,

Patrice Nordmann

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00321-20

Subject(s) - ceftazidime/avibactam , klebsiella pneumoniae , avibactam , ceftazidime , microbiology and biotechnology , beta lactamase inhibitors , biology , medicine , chemistry , antibiotics , bacteria , escherichia coli , biochemistry , genetics , gene , pseudomonas aeruginosa

KPC-50 is a KPC-3 variant identified from aKlebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research